Cellromax Science셀로맥스사이언스
471820 · KOSDAQ · ₩471820 · 셀로맥스사이언스
₩3,965▼ ₩100 (2.46%)End-of-day · Oct 29, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | |
|---|---|---|
| Revenue | ₩22B | ₩22B |
| Cost of sales | ₩12B | ₩9.3B |
| Gross profit | ₩11B | ₩12B |
| Operating income | ₩2.8B | ₩5.5B |
| Net income | ₩3B | ₩3.8B |
| Net income to shareholders | ₩3B | ₩3.8B |
Balance sheet
| 2025 | 2024 | |
|---|---|---|
| Total assets | ₩51B | ₩49B |
| Current assets | ₩14B | ₩31B |
| Cash and equivalents | ₩678M | ₩1.1B |
| Total liabilities | ₩4B | ₩4.6B |
| Current liabilities | ₩2.8B | ₩3.2B |
| Borrowings | — | ₩983M |
| Total equity | ₩47B | ₩45B |
| Shareholders' equity | ₩47B | ₩45B |
Cash flow
| 2025 | 2024 | |
|---|---|---|
| Cash from operations | ₩1.8B | ₩6.3B |
| Capital spending | ₩79M | ₩206M |
| Free cash flow | ₩1.7B | ₩6.1B |
| Dividends paid | ₩3.4B | — |
Consolidated where available. Amounts in won.
Also known as: Cellromax Science / 셀로맥스사이언스 / 471820 / KRX:471820
Source: KRX statistical information